DexCom, Inc.

DexCom, Inc.

Manufactures and distributes medical device software for diabetes care

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying DexCom's stock with a target price of $132.95, indicating strong growth potential.

Above Average

Financial Health

DexCom is performing well with strong revenue and cash flow, demonstrating good profitability and financial stability.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring DXCM

At-Home Treatment Revolution | FDA Approval Impact

At-Home Treatment Revolution | FDA Approval Impact

The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.

Published: September 1, 2025

Explore Basket
At-Home Healthcare Stocks Explained | FDA Approval

At-Home Healthcare Stocks Explained | FDA Approval

The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.

Published: August 30, 2025

Explore Basket
Wearable Tech IP Wars: What Investors Should Know

Wearable Tech IP Wars: What Investors Should Know

Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.

Published: August 21, 2025

Explore Basket
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

Published: August 19, 2025

Explore Basket
Digital Therapeutics & Prescription Apps

Digital Therapeutics & Prescription Apps

Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.

Published: June 17, 2025

Explore Basket
Digital Therapeutics

Digital Therapeutics

Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.

Published: June 17, 2025

Explore Basket
Bio-Hacking Portfolio

Bio-Hacking Portfolio

Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Recurring revenue growth

Consumable sensors and subscription services support revenue predictability, though sales can fluctuate with reimbursement and competitive dynamics.

Product innovation pipeline

Smaller sensors, improved accuracy and system integrations keep the product roadmap active, but technical or regulatory setbacks can affect adoption.

🌍

Global expansion potential

International markets present sizeable opportunity as CGM adoption rises, balanced by differing regulatory regimes and payer systems that can slow rollout.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

TMO

Thermo Fisher Scientific, Inc.

Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.

ISRG

Intuitive Surgical, Inc.

A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties

Frequently asked questions